In the sensitivity analyses using GRS-AD excluding a SNP in APOE region (Supplementary Tables 3 and 4), the estimated effect sizes and directions on CSF p-tau/Aβ and visuospatial score did not change meaningfully, suggesting that GRS-AD other than the APOE region may also contribute to CSF AD biomarkers and visuospatial dysfunction in PD patients. This evidence concerns the gene MAPT and Parkinson disease.